ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
HHKEX:15413.00
HKD
-0.13
(-4.31%)
ISIN
CNE100006624
Return %
Stock
S&P 500
1Y
-70.05
14.20
3Y
-89.19
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Wen Zhi Tian
- Full Time Employees
- 202
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Unit 15 Zhangjiang Science City SH China 210210
- IPO Date
- Sep 5, 2023
- Website
- cn.immuneonco.com
- Similar Companies
- Business
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a clinical-stage biotechnology company focused on developing next-generation immuno-oncology therapies that harness both innate and adaptive immune systems to treat cancer and other diseases. Founded in June 2015 and headquartered in Shanghai, China, the company operates primarily in the domestic Chinese market and internationally through partnerships, with a pipeline of over ten innovative drug candidates across 11 ongoing clinical programs targeting hematologic malignancies, solid tumors, metabolic diseases, and cardiovascular conditions. Its core products include IMM01 (timdarpacept), a next-generation SIRPα-Fc fusion protein in Phase II/III for myelodysplastic syndromes, acute myeloid leukemia, and solid tumors such as non-small cell lung cancer; IMM0306 (amulirafusp alfa), a CD20xCD47 bispecific antibody with strong ADCC, ADCP, and CDC activity; IMM2510, a PD-L1xVEGF bispecific antibody demonstrating 62% overall response rate in Phase II non-small cell lung cancer trials combined with chemotherapy; IMM27M, a next-generation anti-CTLA-4 antibody; IMM72/IMC-003, an ActRIIA fusion protein; and additional candidates like those targeting LILRB family receptors for immune suppression reversal in tumors and autoimmune diseases. In August 2024, ImmuneOnco entered a collaboration worth over $2 billion with Axion Bio, Inc. (a subsidiary of Instil Bio, Inc.), granting ex-Greater China rights to IMM2510 and IMM27M in exchange for upfront and milestone payments totaling at least $35 million received to date, including a $5 million clinical milestone in August 2025; the company retains Greater China rights and continues advancing IMM2510's Phase III plans and U.S. Phase I launch in late 2025, while progressing IMM01 toward Phase III readouts in 2026.